retatrutide phase 2 trial type 2 diabetes results 2024

retatrutide phase 2 trial type 2 diabetes results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Lilly's triple agonist, retatrutide, demonstrated

Name: retatrutide phase 2 trial type 2 diabetes results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Lilly's triple agonist, retatrutide, demonstrated
Brand: ctstranslates.com
SKU: 8291329442
Price: 28.75 USD
Availability: InStock
Rating: 4.3807 (17 reviews)

SKU: 8291329442

4.4

EUR28.75 EUR55.75

Pay in 4 interest-free payments of $7.19 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Description

As weight-loss drugs, some members of this class may promote the shedding of more than Researchers studying GLP-1 found that the hormone has receptors and effects outside the gut

3(10):e2020969 Cigna Healthcare

10.1016/s0140-6736(87)91194-9 49 KuH.ChenW.SuM

Both doses significantly outperformed the placebo across all measured outcomes

DIY dose splitting/dilution: Some patients may use insulin syringes or count clicks on the pen to draw out smaller amounts than the lowest marketed dose, or dilute the drug to create microdoses